Holen Sie sich die Stockscreener-App
11.96
3.37%
0.39
Handel nachbörslich:
11.99
0.03
+0.25%
Schlusskurs vom Vortag:
$11.57
Offen:
$11.6
24-Stunden-Volumen:
6.82M
Relative Volume:
1.19
Marktkapitalisierung:
$8.16B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
2.1168
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
+2.66%
1M Leistung:
+5.28%
6M Leistung:
+14.45%
1J Leistung:
+5.28%
1-Tages-Spanne:
$11.57
$11.97
1-Wochen-Bereich:
$10.90
$11.97
52-Wochen-Spanne:
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Vergleichen Sie ROIV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
11.96 | 7.90B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Roivant plans $500M new share repurchase as brepocitinib data readout nears - MSN
Roivant Sciences Ltd. Approaches Psychological Resistance Level2025 Big Picture & Weekly Market Pulse Alerts - 선데이타임즈
Roivant Sciences’ (ROIV) Aggressive Buybacks Amid Losses: Commitment to Shareholders or Growth Uncertainty? - simplywall.st
Roivant Sciences Earnings Call: Progress Amid Challenges - TipRanks
Why Roivant Sciences Stock Bounced Back on Tuesday - Mitrade
Roivant Sciences shares rise 2.91% intraday after announcing a $500 million share repurchase program. - AInvest
Chairman on Gubra CEO change: Henrik Blou wants to try something different - medwatch.com
Leerink Partners raises Roivant Sciences stock price target to $18 on lower share count By Investing.com - Investing.com South Africa
Roivant Sciences Q1 2025 Earnings Call Highlights: Strong Cash Position and Share Repurchase Amidst Legal and Market Challenges - AInvest
Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Why Roivant Sciences Ltd. stock attracts strong analyst attentionHyper-Growth Screener - classian.co.kr
Roivant Sciences Reports Q1 2025 Financial Results - TipRanks
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update - GlobeNewswire
Why Roivant Sciences Stock Was Slipping on Monday - Mitrade
Roivant Sciences Sees Losses Grow But Investors Hold Steady - Finimize
Roivant Sciences Q1 2026 Earnings Call Transcript - MarketBeat
Roivant Deepens Its Losses But Keeps Investors On Board - Finimize
Roivant Sciences Reports Q1 EPS of 33c, Revenue of $2.17M, and Initiates $1.5B Share Buyback Program - AInvest
Roivant Sciences Ltd. announces an Equity Buyback for $500 million worth of its shares. - MarketScreener
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024. - MarketScreener
Roivant's Q1 2025 Earnings Call: Unraveling the Contradictions in Brepo's DM Market Positioning and Efficacy Expectations - AInvest
Roivant Sciences Ltd. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Transcript : Roivant Sciences Ltd., Q1 2026 Earnings Call, Aug 11, 2025 - MarketScreener
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Roivant Sciences earnings missed by $0.08, revenue fell short of estimates - Investing.com South Africa
Roivant Sciences Q1 Swings to Loss, Revenue Falls - MarketScreener
Biopharma firm Roivant's Q1 revenue declines, net loss widens to $273.9 mln - MarketScreener
Roivant Sciences Ltd. (ROIV) Misses Q1 EPS by 8c - StreetInsider
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q1 Revenue $2.2M, vs. FactSet Est of $7.3M - MarketScreener
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q1 Net Loss $0.33 a Share, vs. FactSet Est of $0.28 Loss - MarketScreener
Will Roivant Sciences Ltd. outperform the marketAI Intraday Market Movement Prediction Tool - Newser
Will Roivant Sciences Ltd. see short term momentumStrong Buy Signal Summary with Entry Zone - Newser
How high can Roivant Sciences Ltd. stock goDaily Entry Opportunity Forecasting Tool - Newser
Is Roivant Sciences Ltd. stock a good hedge against inflationTechnical Reversal Pattern Summary and Tracker - Newser
Roivant Sciences Earnings Expectations: A Closer Look at the Company's Performance and Analyst Sentiments - AInvest
Roivant Sciences (ROIV) to Release Earnings on Monday - Defense World
What makes Roivant Sciences Ltd. stock price move sharplyChart Driven Opportunity Scanner with Alerts - Newser
Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday - Investing.com Australia
Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday By Investing.com - Investing.com South Africa
A Glimpse of Roivant Sciences's Earnings Potential - 富途牛牛
What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings - Yahoo Finance
Roivant Sciences Ltd. shares fall 1.12% intraday as Sumitomo Pharma submits application for Parkinson's disease treatment. - AInvest
ROIV’s Market Whiplash: 9.51% YTD Rise, 8.29% Rise in 30 Days - investchronicle.com
Published on: 2025-08-05 19:46:06 - Newser
Sector ETF Data Correlates with Strength in Roivant Sciences Ltd.Exit Ready Momentum Stock Watchlist Expanded - beatles.ru
What analysts say about Roivant Sciences Ltd. stockDynamic investment opportunities - Jammu Links News
What is the risk reward ratio of investing in Roivant Sciences Ltd. stockAchieve rapid wealth accumulation with smart picks - Jammu Links News
Why is Roivant Sciences Ltd. stock attracting strong analyst attentionMaximize returns with effective portfolio management - Jammu Links News
How does Roivant Sciences Ltd. generate profit in a changing economyTrack emerging stocks with high growth potential - Jammu Links News
What is the dividend policy of Roivant Sciences Ltd. stockCapitalize on momentum stocks early - Jammu Links News
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):